Application

Software to determine prospective staging in the menopausal transition.

Key Benefits

• Allows users to see what STRAW+10 stage they are in for any given week, where menstrual bleeding is tracked.
• Can be used by patients and physicians to track reproductive aging without blood work and a doctor’s visit.
• Help guide users through the menopausal transition and allow them to seek additional care as necessary to mitigate the symptoms associated with perimenopause.

Market Summary

Perimenopause is a process that occurs when the body naturally transitions to menopause, marking the end of the reproductive years. During this time, the body’s production of estrogen and progesterone fluctuates, the menstrual cycle lengthens and may become irregular before the final menstrual period, and ovulation may become erratic and then cease. The menopausal transition is a sensitive time for women, when they may face elevated risks for adverse health outcomes, including mental health disturbances, cognitive decline, and vasomotor symptoms. Perimenopause is defined by the Stages of Reproductive Aging Workshop + 10 (STRAW+10). A limitation in the field is the lack of a method/tool that allows for the prospective staging of where women are in the menopause transition.

Technical Summary

The inventors have developed a technology that aims to overcome the current challenges associated with care during the menopausal transition by creating software that utilizes prospective self-reported menstrual bleeding data to identify the appropriate menopausal stage based on the STRAW+10 criteria for individuals. Data is collected from individuals through weekly surveys. The software then analyzes this user data using an algorithm created by the inventors, examining various factors to identify the STRAW+10 stage the user was in for that week. By doing this analysis on a weekly basis, the software can consistently and reliably track the user’s stage in the menopausal transition over time. This method for prospective reproductive staging could serve as a valuable tool for many individuals, including researchers, physicians, and patients.

Development Stage

Software and license finalized with planned release by end of 2025.